Vanessa M McMahan1, Courtney Moreno2, Alia Al-Tayyib3, Timothy W Menza4, Edwin Roberto Orellana5, Amisha Bhattarai5, Joanne D Stekler, Sara N Glick. 1. From the Department of Medicine, University of Washington. 2. HIV/STD Program, Public Health - Seattle & King County, Seattle, WA. 3. Denver Public Health, Denver Health and Hospital Authority, Denver, CO. 4. HIV/STD/TB Program, Center for Public Health Practice, Oregon Public Health Division. 5. Portland State University, Regional Research Institute for Human Services, Portland, OR.
Abstract
BACKGROUND: In the United States, cisgender men who have sex with men (MSM) who use methamphetamine are at substantial risk for HIV and can benefit from pre-exposure prophylaxis (PrEP). METHODS: We used data from the National HIV Behavioral Surveillance 2017 survey from Seattle, WA; Portland, OR; and Denver, CO, to estimate PrEP awareness and use in the past 12 months among MSM who use methamphetamine. We then compared these estimates with participants who do not use methamphetamine but meet other criteria for PrEP use (i.e., condomless anal sex or a bacterial sexually transmitted infection). We explored reasons for not using PrEP and challenges using PrEP. RESULTS: Of the 1602 MSM who participated in the 2017 National HIV Behavioral Surveillance survey in Seattle, WA; Portland, OR; and Denver, CO, 881 met the inclusion criteria for this study, of whom 88 (10%) reported methamphetamine use in the past 12 months. Most (95%) participants had heard of PrEP, and 35% had used it in the past 12 months. Pre-exposure prophylaxis awareness was lower among MSM who used methamphetamine (P = 0.01), but use was not different (P = 0.26). Among those who had not used PrEP, the most common reason for not using it was not thinking one's HIV risk was high enough (51%). Men who have sex with men who used methamphetamine were more likely to report that they were not sure PrEP would prevent them from getting HIV (38% vs. 19%, P = 0.002). CONCLUSIONS: These results highlight the need for continued efforts to educate and promote PrEP uptake among MSM, particularly those who use methamphetamine.
BACKGROUND: In the United States, cisgender men who have sex with men (MSM) who use methamphetamine are at substantial risk for HIV and can benefit from pre-exposure prophylaxis (PrEP). METHODS: We used data from the National HIV Behavioral Surveillance 2017 survey from Seattle, WA; Portland, OR; and Denver, CO, to estimate PrEP awareness and use in the past 12 months among MSM who use methamphetamine. We then compared these estimates with participants who do not use methamphetamine but meet other criteria for PrEP use (i.e., condomless anal sex or a bacterial sexually transmitted infection). We explored reasons for not using PrEP and challenges using PrEP. RESULTS: Of the 1602 MSM who participated in the 2017 National HIV Behavioral Surveillance survey in Seattle, WA; Portland, OR; and Denver, CO, 881 met the inclusion criteria for this study, of whom 88 (10%) reported methamphetamine use in the past 12 months. Most (95%) participants had heard of PrEP, and 35% had used it in the past 12 months. Pre-exposure prophylaxis awareness was lower among MSM who used methamphetamine (P = 0.01), but use was not different (P = 0.26). Among those who had not used PrEP, the most common reason for not using it was not thinking one's HIV risk was high enough (51%). Men who have sex with men who used methamphetamine were more likely to report that they were not sure PrEP would prevent them from getting HIV (38% vs. 19%, P = 0.002). CONCLUSIONS: These results highlight the need for continued efforts to educate and promote PrEP uptake among MSM, particularly those who use methamphetamine.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Vanessa M McMahan; Aleks Martin; Lindsay Garske; Lauren R Violette; Michele P Andrasik; Jared M Baeten; Caleb Banta-Green; Joanne D Stekler Journal: Sex Health Date: 2019-04 Impact factor: 2.706
Authors: Susan P Buchbinder; David V Glidden; Albert Y Liu; Vanessa McMahan; Juan V Guanira; Kenneth H Mayer; Pedro Goicochea; Robert M Grant Journal: Lancet Infect Dis Date: 2014-03-07 Impact factor: 25.071
Authors: Duncan A MacKellar; Kathleen M Gallagher; Teresa Finlayson; Travis Sanchez; Amy Lansky; Patrick S Sullivan Journal: Public Health Rep Date: 2007 Impact factor: 2.792
Authors: Beryl A Koblin; Marla J Husnik; Grant Colfax; Yijian Huang; Maria Madison; Kenneth Mayer; Patrick J Barresi; Thomas J Coates; Margaret A Chesney; Susan Buchbinder Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Elizabeth Kaplun; Richard J Martino; Kristen D Krause; Michael Briganti; Paul A D'Avanzo; Perry N Halkitis Journal: Int J Environ Res Public Health Date: 2022-01-09 Impact factor: 3.390